Document is current
Any future updates will be listed below
-
Authors
Busschots, Dana https://orcid.org/0000-0003-0887-4119
Kremer, Cécile
Bielen, Rob
Koc, Özgür M.
Heyens, Leen
Nevens, Frederik
Hens, Niel
Robaeys, Geert
- License Information
-
More Information
Article History
Received: 6 November 2021
Accepted: 14 November 2022
First Online: 24 November 2022
Declarations
:
: Not applicable
: Not applicable
: D.B. has received travel grants from AbbVie and Gilead Sciences; R.B. has received travel grants from AbbVie, Gilead Sciences and Merck Sharp & Dohme (MSD) and research grants from Gilead and MSD; O.K. has received a travel grant from Gilead Sciences and his institution received research grants from Gilead Sciences and CyTuVax BV; F.N. has received research grants, consultancy agreements and travel grants from UCB, Ipsen, Roche, Astellas, Ferring, Novartis, Janssen-Cilag, Abbvie, Gilead, CAF, Intercept, Gore, Bristol-Myers Squibb (BMS), MSD, Promethera Biosciences, Ono Pharma, Durect; N.H. reports grants from GlaxoSmithKline, grants from Johnson & Johnson pharmaceuticals and grants from Pfizer; G.R. has received research grants from AbbVie, Janssen Pharmaceuticals, MSD, and consultancy agreements for AbbVie, BMS, Gilead Sciences and MSD. All other co-authors report no competing interests.
